AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21497479 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal commitment
Number of subjects: 2
Study 21497479 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficacy beliefs
Number of subjects: 2
Study 19740580 — intervention group
Group type: COMPARATOR
Intervention: Classic cinch suture
Number of subjects: 40
Study 19740580 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified cinch suture
Number of subjects: 40
Study 18671458 — intervention group
Group type: EXPERIMENTAL
Intervention: Apricitabine 1200 mg administered after fasting
Number of subjects: 20
Study 18671458 — intervention group
Group type: EXPERIMENTAL
Intervention: Apricitabine 1200 mg administered after a high-fat meal
Number of subjects: 20
Study 18671458 — intervention group
Group type: COMPARATOR
Intervention: Comparison of fasting vs high-fat meal administration
Number of subjects: 20
Study 15750359 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized homeopathic medicine
Number of subjects: 53
Study 15750359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 12019669 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 30
Study 12019669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10658408 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine 100 mg before surgical incision (group-K1)
Number of subjects: 39
Study 10658408 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ketamine after laparotomy (group-K2)
Number of subjects: 39
Study 10658408 — intervention group
Group type: COMPARATOR
Intervention: Control group (group-C)
Number of subjects: 39
Study 7495944 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg b.d.
Number of subjects: 0
Study 7495944 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg b.d.
Number of subjects: 0
Study 7495944 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg b.d., intravenous drip infusion
Number of subjects: 0
Study 7495944 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg b.d., bolus injection
Number of subjects: 0
Study 2207868 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% indomethacin
Number of subjects: 46
Study 2207868 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% prednisolone acetate
Number of subjects: 46
Study 2207868 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears (control group)
Number of subjects: 46
Study 657166 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazinate
Number of subjects: 0
Study 657166 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrazofurin
Number of subjects: 0
Study 657166 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 30350398 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid + vitamin B12
Number of subjects: 57
Study 30350398 — intervention group
Group type: EXPERIMENTAL
Intervention: Monomeric and oligomeric flavanols (MOF)
Number of subjects: 57
Study 26658126 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based dosing of 0.5 mg kg(‐1) twice daily
Number of subjects: 84
Study 26658126 — intervention group
Group type: COMPARATOR
Intervention: Fixed dose of 40 mg daily
Number of subjects: 84
Study 24517899 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care with intermittent changes to body and head position, reduced sandbag compression time to 1 hour, and allowed ambulation after 6 hours.
Number of subjects: 80
Study 24517899 — intervention group
Group type: COMPARATOR
Intervention: Routine care with 6-24 hours of bed rest in supine position and sandbag compression for 6 hours.
Number of subjects: 80
Study 22486334 — intervention group
Group type: EXPERIMENTAL
Intervention: Online version of TLFB assessment
Number of subjects: 102
Study 22486334 — intervention group
Group type: COMPARATOR
Intervention: In-person interview format
Number of subjects: 102
Study 20213013 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucoadhesive lipid-based bioerodable tablet
Number of subjects: 20
Study 20213013 — intervention group
Group type: COMPARATOR
Intervention: Biotène mouthwash
Number of subjects: 20
Study 18413214 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine HCl
Number of subjects: 60
Study 18413214 — intervention group
Group type: COMPARATOR
Intervention: Combination of vitamins B(1) and B(6) tablets
Number of subjects: 60
Study 15814161 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg, twice daily, for 16 weeks)
Number of subjects: 0
Study 15814161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12219852 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance treatment to deceptive persuasive messages
Number of subjects: 0
Study 12219852 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance treatment
Number of subjects: 0
Study 12219852 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure that dispelled participants' illusions of invulnerability
Number of subjects: 0
Study 10379449 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-impregnated catheters (Erlanger silver catheters)
Number of subjects: 41
Study 10379449 — intervention group
Group type: COMPARATOR
Intervention: Control catheters (Quinton Instrument Co.)
Number of subjects: 41
Study 8966498 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent cyclic therapy (ICT) with etidronate
Number of subjects: 88
Study 8966498 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 88
Study 1836677 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician education intervention
Number of subjects: 305
Study 1836677 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients seen before the intervention)
Number of subjects: 305
Study 6670855 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% acyclovir in an aqueous cream base
Number of subjects: 113
Study 31336366 — intervention group
Group type: EXPERIMENTAL
Intervention: White Light Imaging (WLI)
Number of subjects: 127
Study 31336366 — intervention group
Group type: EXPERIMENTAL
Intervention: Linked Color Imaging (LCI)
Number of subjects: 127
Study 31336366 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-observer agreement for WLI
Number of subjects: 127
Study 31336366 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-observer agreement for LCI
Number of subjects: 127
Study 30859993 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS) treatment
Number of subjects: 1
Study 30859993 — intervention group
Group type: COMPARATOR
Intervention: Maintenance therapy (not performed)
Number of subjects: 1
Study 28344176 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) with a margin dose >20 Gy
Number of subjects: 232
Study 28344176 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) with a margin dose ≤20 Gy
Number of subjects: 232
Study 28344176 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 232
Study 27123421 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (loading dose 1 μg/kg over 15 minutes, maintenance 0.5 μg/kg/h)
Number of subjects: 90
Study 27123421 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (loading dose 50 mg/kg over 15 minutes, maintenance 15 mg/kg/h)
Number of subjects: 90
Study 27123421 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 90
Study 24268564 — intervention group
Group type: EXPERIMENTAL
Intervention: Rothschild Scale for Antidepressant Tachyphylaxis® (RSAT)
Number of subjects: 483
Study 24268564 — intervention group
Group type: EXPERIMENTAL
Intervention: Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ)
Number of subjects: 483
Study 24268564 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheehan Disability Scale (SDS)
Number of subjects: 483
Study 24268564 — intervention group
Group type: EXPERIMENTAL
Intervention: Apathy Evaluation Scale‐Clinician rated version (AES‐C)
Number of subjects: 483
Study 22615018 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced propofol sedation (BPS)
Number of subjects: 206
Study 22615018 — intervention group
Group type: COMPARATOR
Intervention: Propofol monosedation
Number of subjects: 206
Study 20299362 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release niacin combined with laropiprant (ERN-L)
Number of subjects: 1547
Study 20299362 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release niacin alone (ERN)
Number of subjects: 1547
Study 20299362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1547
Study 18797091 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper hand
Number of subjects: 30
Study 18797091 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper rotary
Number of subjects: 30
Study 18797091 — intervention group
Group type: EXPERIMENTAL
Intervention: ProFile
Number of subjects: 30
Study 18161210 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 143
Study 18161210 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 143
Study 12452452 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin at 80 mg/m2 x 3, followed by paclitaxel at 140 mg/m2 over 96 h x 3, then 5‐FU at doses of 1285, 1470, or 1655 mg/m2 by continuous intravenous infusion over 72 h x 3
Number of subjects: 19
Study 12452452 — intervention group
Group type: COMPARATOR
Intervention: Dose-dense regimen
Number of subjects: 19
Study 10088585 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical acupuncture plus comprehensive rehabilitation (n = 59)
Number of subjects: 128
Study 10088585 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive rehabilitation only (n = 59)
Number of subjects: 128
Study 8747680 — intervention group
Group type: EXPERIMENTAL
Intervention: Meridol(R)
Number of subjects: 30
Study 8747680 — intervention group
Group type: COMPARATOR
Intervention: Darjeeling tea (< 0.2 ppm F‐)
Number of subjects: 30
Study 8747680 — intervention group
Group type: COMPARATOR
Intervention: Control (tap water:< 0.2 ppm F‐)
Number of subjects: 30
Study 1953964 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrahydroaminoacridine (THA) treatment during inpatient phase
Number of subjects: 10
Study 1953964 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term outpatient treatment with THA
Number of subjects: 10
Study 1953964 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 10
Study 6303106 — intervention group
Group type: COMPARATOR
Intervention: CAV (cyclophosphamide, adriamycin, and vincristine)
Number of subjects: 102
Study 6303106 — intervention group
Group type: EXPERIMENTAL
Intervention: CAV plus VP-16-213
Number of subjects: 102
Study 31505491 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporine A (CsA) administered for 12 months after engraftment
Number of subjects: 20
Study 31505491 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporine A (CsA)
Number of subjects: 20
Study 30246505 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose
Number of subjects: 100
Study 30246505 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 100
Study 28357897 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training (MT) for 8 weeks
Number of subjects: 0
Study 28357897 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mindfulness training)
Number of subjects: 0
Study 28357897 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 27078993 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion
Number of subjects: 58
Study 27078993 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise
Number of subjects: 58
Study 27078993 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional drug therapy)
Number of subjects: 58
Study 24491137 — intervention group
Group type: EXPERIMENTAL
Intervention: Taking Healthy Steps (Internet-mediated walking program)
Number of subjects: 239
Study 24491137 — intervention group
Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 239
Study 17936382 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxy‐obtained information from primary caregiver
Number of subjects: 330
Study 17936382 — intervention group
Group type: EXPERIMENTAL
Intervention: Impairment in activities of daily living (ADL)
Number of subjects: 330
Study 17936382 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychiatric symptoms
Number of subjects: 330
Study 15126518 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal system (Striant), applied twice daily for 7 days
Number of subjects: 66
Study 15126518 — intervention group
Group type: COMPARATOR
Intervention: Transdermal patch (Andropatch or Androderm), applied daily for 7 days
Number of subjects: 66
Study 11044760 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 2.5 mg
Number of subjects: 14130
Study 11044760 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 5 mg
Number of subjects: 14130
Study 11044760 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.2 mg
Number of subjects: 14130
Study 11044760 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg
Number of subjects: 14130
Study 11044760 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 14130
Study 11044760 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 14130
Study 11044760 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 14130
Study 9296510 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-sewn anastomosis
Number of subjects: 122
Study 9296510 — intervention group
Group type: COMPARATOR
Intervention: Stapled anastomosis
Number of subjects: 122
Study 7975414 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet therapy with additional provision of vegetables, fruit, and greens
Number of subjects: 0
Study 3547009 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g of glucose in 350 ml of water (GLU)
Number of subjects: 6
Study 3547009 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g of fructose in 350 ml of water (FRU)
Number of subjects: 6
Study 3547009 — intervention group
Group type: COMPARATOR
Intervention: 350 ml of an artificially sweetened and flavored placebo (CON)
Number of subjects: 6
Study 30580490 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated carbon nanoparticles (ACNs) injection (1 ml) in the subserosa around the tumour before colectomy and D3 lymphadenectomy.
Number of subjects: 80
Study 30580490 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ACN injection).
Number of subjects: 80
Study 30580490 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated carbon nanoparticles (ACNs) injection.
Number of subjects: 80
Study 28687711 — intervention group
Group type: EXPERIMENTAL
Intervention: Norwood to Stage 2 Palliation (S2P) interval of 3 to 6 months
Number of subjects: 547
Study 28687711 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 2 Palliation (S2P)
Number of subjects: 547
Study 28687711 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-adjusted, 3-year TFS
Number of subjects: 547
Study 28687711 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors to S2P
Number of subjects: 547
Study 28687711 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-year follow-up after S2P
Number of subjects: 547
Study 28687711 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal timing of S2P
Number of subjects: 547
Study 26427723 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent-inactivated vaccine
Number of subjects: 0
Study 26427723 — intervention group
Group type: EXPERIMENTAL
Intervention: Live-attenuated vaccine
Number of subjects: 0
Study 26427723 — intervention group
Group type: COMPARATOR
Intervention: Titer of 1:40
Number of subjects: 0
Study 26427723 — intervention group
Group type: COMPARATOR
Intervention: Titer of 1:80
Number of subjects: 0
Study 25249036 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with at most one negative lifestyle factor (n = 48)
Number of subjects: 502
Study 25249036 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with two negative lifestyle factors (n = 64)
Number of subjects: 502
Study 25249036 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with three negative lifestyle factors (n = 56)
Number of subjects: 502
Study 25249036 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with four negative lifestyle factors (n = 41)
Number of subjects: 502
Study 25249036 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with five or more negative lifestyle factors (n = 14)
Number of subjects: 502
Study 23121733 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD‐EPI eGFR <60 mL/min/1.73m2
Number of subjects: 1098
Study 23121733 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuminuria with eGFR ≥60 mL/min/1.73 m2
Number of subjects: 1098
Study 23121733 — intervention group
Group type: EXPERIMENTAL
Intervention: National Kidney Foundation (NKF) defined CKD
Number of subjects: 1098
Study 23121733 — intervention group
Group type: EXPERIMENTAL
Intervention: MDRD related estimates for eGFR <60 mL/min/1.73 m2
Number of subjects: 1098
Study 19708471 — intervention group
Group type: COMPARATOR
Intervention: Qigong Sensory Training (QST) - a qigong massage intervention, involving 20 sessions over 5 months, with daily parental massage.
Number of subjects: 46
Study 19708471 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 46
Study 18165528 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole administered bimonthly to 107 subjects
Number of subjects: 212
Study 18165528 — intervention group
Group type: COMPARATOR
Intervention: Control group of 105 subjects
Number of subjects: 212
Study 18165528 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole administered to children 5-14 years
Number of subjects: 212
Study 15509817 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional schedule (extended work shifts of 24 hours or more)
Number of subjects: 634
Study 11903763 — intervention group
Group type: EXPERIMENTAL
Intervention: One-hour didactic session, the use of well‐built clinical question cards, and practical sessions in clinical question building.
Number of subjects: 48
Study 11903763 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 48
Study 9389844 — intervention group
Group type: EXPERIMENTAL
Intervention: Single, end-holed extradural catheters
Number of subjects: 364
Study 9389844 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-orifice extradural catheters
Number of subjects: 364
Study 7702414 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard duration balloon inflation (< or = 3 min)
Number of subjects: 27
Study 7702414 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged duration balloon inflation (>= 12 min)
Number of subjects: 27
Study 7702414 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 27
Study 3584580 — intervention group
Group type: EXPERIMENTAL
Intervention: PA Patch
Number of subjects: 9
Study 3584580 — intervention group
Group type: COMPARATOR
Intervention: Finn Chamber
Number of subjects: 9
Study 31478095 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT) + Exercise
Number of subjects: 42
Study 31478095 — intervention group
Group type: COMPARATOR
Intervention: Placebo HILT + Exercise
Number of subjects: 42
Study 28901958 — intervention group
Group type: EXPERIMENTAL
Intervention: Montmorency tart cherry juice (240 mL 2 times/d for 2 weeks)
Number of subjects: 8
Study 26669504 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno V(+) etch
Number of subjects: 112
Study 26669504 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE non-etch
Number of subjects: 112
Study 26669504 — intervention group
Group type: COMPARATOR
Intervention: Clearfil SE Bond (etch)
Number of subjects: 112
Study 26669504 — intervention group
Group type: COMPARATOR
Intervention: Xeno V(+) (non-etch)
Number of subjects: 112
Study 24763930 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg once daily; 15 mg once daily for creatinine clearance of 30‐49 mL/min
Number of subjects: 932
Study 24763930 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 932
Study 24763930 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 932
Study 24429202 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and calcifediol
Number of subjects: 171
Study 24429202 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 171
Study 24429202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 20544937 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular BoNT‐A injections at 6‐month intervals in the tibialis posterior and peroneus longus.
Number of subjects: 10
Study 20544937 — intervention group
Group type: COMPARATOR
Intervention: Control leg received no injections.
Number of subjects: 10
Study 18773722 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinetic pattern with circular illusory apertures revealing drifting gratings
Number of subjects: 0
Study 18773722 — intervention group
Group type: EXPERIMENTAL
Intervention: Static jagged diamond with varying shapes and edge discontinuities
Number of subjects: 0
Study 17061020 — intervention group
Group type: EXPERIMENTAL
Intervention: Percussive ventilation (IMP2 Breas, Sweden) 10 min twice/day in addition to chest physiotherapy
Number of subjects: 46
Study 17061020 — intervention group
Group type: COMPARATOR
Intervention: Chest physiotherapy (control)
Number of subjects: 46
Study 14581257 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated medication nurses
Number of subjects: 24
Study 14581257 — intervention group
Group type: COMPARATOR
Intervention: General nurses
Number of subjects: 24
Study 14581257 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated medication nurses at hospital B
Number of subjects: 24
Study 14581257 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated medication nurses at hospital A
Number of subjects: 24
Study 14581257 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated medication nurses in surgical units at hospital A
Number of subjects: 24
Study 14581257 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated medication nurses in medical units
Number of subjects: 24